PIK3CD and cancer: Collectively, these data (Fig. 4, A to C and J) demonstrated the effective molecular guided targeting and inhibition of AKT activity and invasive capacity of mutant PtenG129E/+ cancer cells by treatment with the pan-PI3K inhibitor BKM120 in a time-resolved manner.